Table 1 patients’ characteristics at baseline
From: Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
|  | all patients | ECRS (+) group | ECRS (−) group | p value between two groups |
|---|---|---|---|---|
n = 27 | n = 16 | n = 11 | ||
gender (male), n (%) | 8 (30) | 5 (31) | 3 (27) | 0.99 < a |
age (year-old), (range) | 56.3 (11.8), (35–79) | 54.2 (11.3), (35–71) | 59.3 (12.5), (36–79) | 0.31b |
duration of asthma (year), (range) | 19.6 (11.9), (4–43) | 23.5 (10.6), (8–43) | 45.4 (22.6), (4–39) | 0.020b |
BMI(kg/m2) | 22.8 (4.7) | 22.1 (4.5) | 23.9 (4.9) | 0.26b |
smoking (never / former / current), n | 20 / 7 / 0 | 12 / 4 / 0 | 8 / 3 / 0 | 0.99 < a |
atopic / non atopic, n | 21 / 6 | 15 / 1 | 6 / 5 | 0.027a |
previous omalizumab, n (%) | 8 (30) | 6 (38) | 2 (18) | 0.40a |
initial treatments use | ||||
 —ICS/LABA, n(%) | 27 (100) | 16 (100) | 11 (100) | NA |
 —ICS dose(μg)c, mean (SD) | 963 (222) | 950 (137) | 982 (316) | 0.60 |
 —LAMA, n(%) | 13 (48) | 5 (31) | 8 (73) | 0.054 |
 —LTRA, n(%) | 23 (85) | 13 (81) | 10 (91) | 0.62 |
 —xanthine derivative, n(%) | 17 (63) | 9 (56) | 8 (73) | 0.45 |
 —maintenance therapy of OCS, n (%) | 16 (59) | 10 (63) | 6 (55) | 0.71a |
 —daily dose of OCS (mg)d, (range) | 8.4 (5.6), (0.5–20) | 7.0 (4.8), (0.5–15) | 10.8 (6.5), (5–20) | 0.29b |
comorbidities, n (%) | ||||
 —ECRS | 16 (59) | 16 (100) | – | NA |
 —eosinophilic otitis media | 9 (33) | 9 (56) | 0 (0) | NA |
 —EGPA | 4 (15) | 4 (25) | 0 (0) | NA |
number of injection, median (range) | 9 (2–17) | 9.5 (4–17) | 7 (2–12) | 0.17b |
duration of observation (month), median (range) | 11 (4–17) | 12.5 (6–17) | 10 (4–12) | 0.014b |